
Trump Admin Reclassifies Cannabis: Impact on Research & Business
The Trump administration has initiated a federal reclassification of cannabis, moving it from Schedule I to Schedule III under the DEA's controlled substances framework. This change does not legalize the drug federally but significantly reduces regulatory barriers. Key impacts include allowing cannabis companies to deduct standard business expenses and improving banking access. The move follows previous efforts by both administrations and is seen as a major policy shift. Experts suggest this will boost scientific research into cannabis's medical potential while supporting industry stability.






















